Hot Topics / Chinese Biotech
PharmaBoardroom sat down with more than 25 biotech CEOs in China in 2019. We analyzed the contents of the…
Top Stories
AMR / The Fight Against Superbugs: Properly Incentivising Antimicrobial R&D Is Key
BIO's Greg Frank outlines the alarming growth of drug-resistant infections and the steps that need to be taken to combat this rapidly emerging global health threat. Drug-resistant superbugs are…
MEA / UAE to Boost Health Research Capabilities as Part of 50-Year Strategy
The United Arab Emirates’ Cabinet, the de facto executive branch of the federation, recently announced a set of…
Canada / Global Pharma has Reinvented R&D: Will Canadian Start-Ups Lead the Next Phase?
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the…
Country Report / New Puerto Rico Pharma Report January 2020 Out Now
Puerto Rico had to rebuild itself – in many cases quite literally – after the devastation wrought by Hurricane…
Webinar / The Future of Biopharma – Predicting the Forces that will Shape the Biopharma Industry
With the recent publication of Ten years on: Measuring the Return from Pharmaceutical Innovation…
2020 Trends / A More Measured Tone at the J.P. Morgan Healthcare Conference
David Crean summarises the mood at the recent J.P. Morgan Healthcare Conference 2020 in San Francisco, noting a…
In Conversation
Chip Davis – President & CEO, Association for Accessible Medicines (AAM), USA
The AAM’s Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple public and private actors and offers insight as to why there is great room for improvement in the uptake of biosimilar drugs. The question, as we move forward with these six- and even seven-figure…
Latest Reports
Focus on UAE
UAE Accelerated Drug Approvals
The UAE ranks among the world's fastest for new drug approvals, ranking first…
UAE Pharma’s First Steps into North America
LIFEPharma, a subsidiary of UAE-based VPS Healthcare, has signed a Dh 200…
UAE: Making Strides Against Lifestyle Diseases
The UAE's rapid economic growth over the last half-century has been accompanied…
The Middle East: Stepping Stone to Global Leadership
PharmaBoardroom highlights three pharma executives whose experience in the…
Read more: UAE >>
Focus on Puerto Rico
A Collaborative Approach to Fighting Diabetes in Puerto Rico
In Puerto Rico, approximately 16 percent of the adult population has diabetes,…
Pharma Faces: Jorge Rodríguez, PACIV, Puerto Rico
Over the last 22 years, Jorge Rodríguez has grown Puerto Rican industrial…
Romark: Heading the New Wave of Puerto Rican Pharma…
Headquartered in Tampa, Florida, Romark focuses on developing innovative…
Puerto Rican Logistics: Through the Hurricane
Puerto Rico’s export-driven economy could not exist without someone moving,…
Read more: Puerto Rico >>
Focus on China
Hot Topics in Chinese Biotech
PharmaBoardroom sat down with more than 25 biotech CEOs in China in 2019. We…
Chinese Oncology Biotechs to Watch
Cancer is one of the world’s leading causes of death and in China, the…
Hot Topics for MNCs in China
PharmaBoardroom recently analysed the contents of 10 interviews conducted with…
Key Highlights of China’s New Drug Administration Law
On 26 August 2019, the Chinese legislature, the National People’s Congress…
Read more: China >>
Focus on Spain
Most Looked at Countries in 2019
PharmaBoardroom had the opportunity to sit down with over six hundred key…
Spain Medtech Snapshot
Spain's medtech imports have nearly doubled compared to its exports over the…
Esteve: Out with the Old; In with the New
Esteve has long been a family-run business, though in early 2018 the Spanish…
Jazz Pharmaceuticals Spain: Playing to a Different Beat
Though still one of the younger and lesser-known outfits inhabiting the European…
Read more: Spain >>
Focus on France
France Pharma Snapshot 2019
A snapshot of the latest data on the French pharmaceutical industry from…
French Cell & Gene Therapy: Finding the Funding
France – one of the most influential countries in the development of gene…
New France Pharma Report June 2019 Out Now
The latest issue of Healthcare & Life Sciences Review France follows on from…
Most Looked at Countries in 2019
PharmaBoardroom had the opportunity to sit down with over six hundred key…
Read more: France >>
Focus on CEE
Gedeon Richter: Open to Collaboration
As the only one of Hungary’s four historical pharmaceutical manufactures to…
Romania Country Managers: Where are they Now?
PharmaBoardroom takes a look at the careers of five pharma executives who we…
Hungary’s National Champions Betting on Biosimilars
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter,…
Hungary’s First Steps into Digital Healthcare
After years of planning and collaboration with various stakeholders, in 2017 the…
Read more: CEE >>
Focus on USA
US Pharma Rewards its Shareholders
In 2019 big pharma companies prioritised shareholder payouts and dividends, with…
US FDA’s Efforts to Advance the Development of Gene…
Peter Marks, director of the US FDA's Center for Biologics Evaluation and…
FDA Drugs Approved in 2019
In 2019, the US FDA's Center for Drug Evaluation and Research approved 42 novel…
Biosimilars Work. Why Aren’t They Taking Off in the US?
The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar…
Read more: USA >>
Focus on AMR
Antibiotics: Responsibly Making the Drugs Society Needs
Steve Brooks, Advisor to the AMR Industry Alliance, outlines the threat that…
The EC’s concerns for the future of European health
At last week's European Health Forum Gastein (EHFG), the theme surrounded the…
The Fight Against Superbugs: Properly Incentivising…
BIO's Greg Frank outlines the alarming growth of drug-resistant infections and…
The UK to Incentivise Big Pharma Firms to Develop New…
In recent years, apocalyptic conversations around superbugs caused by…